Liang Zeng

Title: Innovations of Liang Zeng in Biopharmaceuticals

Introduction

Liang Zeng is a prominent inventor based in Wuhan, China, known for his contributions to the field of biopharmaceuticals. He has been instrumental in developing innovative antibody technologies that enhance therapeutic efficacy. With a total of 2 patents to his name, Zeng's work focuses on improving the functionality and stability of antibodies.

Latest Patents

Zeng's latest patents include significant advancements in antibody design. The first patent, titled "Modified Fc fragment, antibody comprising same, and application thereof," discusses a modified Fc fragment derived from human IgG1. This innovation features multiple substitutions in the constant region CH2 domain, which significantly reduces the binding ability of the Fc fragment to Fcγ receptors. This reduction minimizes the non-specific activation of T cells by antibodies, such as anti-CD3 antibodies. The second patent, "CD3 antigen binding fragment and application thereof," presents a humanized and multifunctional CD3 antibody. This antibody includes a heavy chain variable region with specific amino acid sequences and a light chain variable region that enhances its specificity for tumor cells or microorganisms. The multifunctional antibody also comprises a fusion peptide that improves biological activity, thermal stability, and acid resistance.

Career Highlights

Liang Zeng is currently associated with Wuhan Yzy Biopharma Co., Ltd., where he continues to push the boundaries of biopharmaceutical research. His work has garnered attention for its potential to revolutionize treatments for various diseases through innovative antibody therapies.

Collaborations

Zeng collaborates with notable colleagues, including Jing Zhang and Lijuan Fang, who contribute to the research and development efforts at Wuhan Yzy Biopharma Co., Ltd. Their combined expertise fosters a dynamic environment for innovation in biopharmaceuticals.

Conclusion

Liang Zeng's contributions to the field of biopharmaceuticals through his innovative patents and collaborative efforts highlight his role as a key inventor in advancing antibody technology. His work promises to enhance therapeutic options and improve patient outcomes in the future.